A phase II trial of temozolomide as a 6‐week, continuous, oral schedule in patients with advanced soft tissue sarcoma
Authors:
- Xavier Garcia del MuroXMXavier Garcia del Muro
- Antonio Lopez‐PousaALAntonio Lopez‐Pousa
- Javier MartinJavier Martin
- Jose M. BuesaJBJose M. Buesa
- Javier Martinez‐TruferoJMJavier Martinez‐Trufero
- Antonio CasadoACAntonio Casado
- Andres PovedaAPAndres Poveda
- Josefina CruzJCJosefina Cruz
- Isabel BoverIBIsabel Bover
- Joan MaurelJMJoan Maurel
- for the Spanish Group for Research on SarcomasFSfor the Spanish Group for Research on Sarcomas
Abstract
BACKGROUND: The objective of this study was to evaluate the activity and toxicity of temozolomide given as an extended schedule in patients with advanced sarcoma.METHODS: Forty‐nine patients with pretreated soft tissue sarcoma (the STS arm) and 18 patients with previously untreated gastrointestinal stromal tumor (the GIST arm) were enrolled onto a 2‐arm, multicenter, Phase II study between November 1999 and July 2001. Temozolomide was administered on a 6‐week, continuous, oral schedule at a dose of 75 mg/m2 per day in 41 patients and, after an amendment, at a dose of 100 mg/m2 per day in 22 patients.RESULTS: Among 45 eligible patients in the STS arm, there were 7 partial responses, for an overall response rate of 15.5% (95% confidence interval [95% CI], 5–26%). Responses were seen in 5 of 11 patients who had gynecologic leiomyosarcoma. The median response duration was 12.5 months (range, 3.9–58.0 mos). In 4 patients, response lasted > 1 year, and 2 of those patients remained progression free for > 3 years. The median time to progression was 2.2 months (95% CI, 1.8–2.5 mos), and the median overall survival was 8.1 months (95% CI, 5.6–10.6 mos). Progression‐free survival rates at 3 months and 6 months were 39.5% and 26%, respectively. In the GIST arm, no responses were noted. Grade 3–4 granulocytopenia, thrombocytopenia, and anemia were observed in 6 patients, 5 patients, and 7 patients, respectively. The most common nonhematologic toxicities were emesis and fatigue.CONCLUSIONS: Temozolomide at the extended schedule was tolerated well and had activity in patients with pretreated soft tissue sarcomas, and especially among patients with gynecologic leiomyosarcoma. Cancer 2005. © 2005 American Cancer Society.Keywords
This publication has 25 references indexed in Scilit:
- A two‐arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomasCancer, 2003
- A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcomaCancer, 2003
- Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesBritish Journal of Cancer, 2003
- Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomasEuropean Journal of Cancer, 2002
- Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma GroupEuropean Journal of Cancer, 1999
- Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group StudyJournal of Clinical Oncology, 1999
- Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS)Annals of Oncology, 1998
- Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trialsCancer Treatment Reviews, 1997
- Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)British Journal of Cancer, 1992
- High-dose DTIC in advanced soft-tissue sarcomas in the adultAnnals of Oncology, 1991